Tumour necrosis factor-α antagonists in the management of rheumatoid arthritis in the elderly: A review of their efficacy and safety

Drugs and Aging

Volumn 26, Issue 8, 2009, Pages 647-664

  Radovits, Beáta J ^a   Kievit, Wietske ^a   Laan, Roland F J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; CANCER RISK; CARDIOVASCULAR DISEASE; CELL AGING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; INFECTION; INFECTION RISK; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

AGED; AGING; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69049115215     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11316460-000000000-00000     Document Type: Review

References (88)

1. Kaipiainen-Seppanen O, Aho K, Isomaki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975-1990. Clin Exp Rheumatol 1996; 14 (5): 537-542
2. Symmons DPM. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16 (5): 707-722 (Pubitemid 35460345)
3. Laiho K, Tuomilehto J, Tilvis R. Prevalence of rheumatoid arthritis and musculoskeletal diseases in the elderly population. Rheumatol Int 2001; 20 (3): 85-87 (Pubitemid 32250117)
4. Bergstrom G, Bjelle A, Sundh V, et al. Joint disorders at ages 70, 75 and 79 years: cross-sectional comparison. Br J Rheumatol 1986; 25 (4): 333-341
5. Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003; 48 (4): 917-926 (Pubitemid 36418233)
6. Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003; 23 (2): 70-74 (Pubitemid 36388751)
7. Linos A, Worthington JW, Ofallon WM, et al. Epidemiology of rheumatoid arthritis in Rochester, Minnesota: study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111 (1): 87-98 (Pubitemid 10207608)
8. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence epidemiology and rheumatoid arthritis. Exp Gerontol 2003; 38 (8): 833-841
9. Makinodan T, Kay MMB. Age influence on the immune system. Adv Immunol 1980; 29: 287-330
10. Fleischmann R, Iqbal I. Risk : benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007; 24 (3): 239-254 (Pubitemid 46457026)
11. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63 Suppl. 2: ii13-7
12. European Medicines Agency. European public assessment report [online]. Available from URL: http://www.emea. europa.eu/htms/human/epar/eparintro.htm [Accessed 2009 May 21]
13. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30 (12): 2563-2571
14. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50 (4): 1051-1065
15. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340 (4): 253-259 (Pubitemid 29063266)
16. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48 (1): 35-45 (Pubitemid 36091645)
17. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343 (22): 1586-1593 (Pubitemid 32162981)
18. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46 (6): 1443-1450
19. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50 (11): 3432-3443 (Pubitemid 39488667)
20. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363 (9410): 675-681 (Pubitemid 38296553)
21. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50 (5): 1400-1411
22. van Riel PL, Freundlich B, MacPeek D, et al. Patientreported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008; 67 (8): 1104-1110
23. Kievit W, Fransen J, Oerlemans AJM, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 2007; 66 (11): 1473-1478 (Pubitemid 350032655)
24. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54 (11): 3399-3407 (Pubitemid 44737150)
25. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34 (5 Suppl. 1): 19-22 (Pubitemid 40502156)
26. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren't they?). Rheumatology (Oxford) 2005; 44 (3): 271-273 (Pubitemid 40361279)
27. Schwartzman S, Fleischmann R, Morgan Jr GJ. Do anti- TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004; 6 Suppl. 2: S3-11
28. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64 (10): 1414-1420 (Pubitemid 41623850)
29. Curtis JR, Patkar N, Xie AY, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56 (4): 1125-1133 (Pubitemid 46608637)
30. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54 (8): 2368-2376 (Pubitemid 44204996)
31. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009 Jul; 68 (7): 1136-1145
32. Dixon WG, Symmons DPM, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56 (9): 2896-2904 (Pubitemid 47502735)
33. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66 (10): 1339-1344 (Pubitemid 47492478)
34. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44 (6): 714-720 (Pubitemid 41487198)
35. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39 (3): 295-299 (Pubitemid 39050474)
36. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295 (19): 2275-2285 (Pubitemid 43736578)
37. Watson K, Symmons D, Griffiths I, et al. The British Society for Rheumatology. Biologics Register. Ann Rheum Dis 2005; 64 Suppl. 4: iv42-3
38. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64 (10): 1421-1426 (Pubitemid 41623851)
39. Askling J, Baecklund E, Granath F, et al. Anti-TNF therapy in RA and risk of malignant lymphomas: relative risks and time-trend in the Swedish Biologics Register. Ann Rheum Dis 2009; 68 (5): 648-653
40. Wolfe F, Michaud K. The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56 (5): 1433-1439 (Pubitemid 46764070)
41. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50 (6): 1740-1751 (Pubitemid 38725085)
42. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156 (2): 336-341
43. Chung ES, Packer M, Lo KH, et al. Randomized, doubleblind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25): 3133-3140 (Pubitemid 36793081)
44. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58 (3): 667-677
45. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116 (5): 305-311 (Pubitemid 38230289)
46. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4 (3): 153-161 (Pubitemid 40488744)
47. Abbas AK, Lichtman AH. Basic immunology. Function and disorders of the immune system. Philadelphia (PA): W.B. Saunders Company, 2001
48. Fulop T, Larbi A, Dupuis G, et al. Ageing, autoimmunity and arthritis: perturbations of TCRsignal transduction pathways with ageing a biochemical paradigm for the ageing immune system. Arthritis Res Ther 2003; 5 (6): 290-302 (Pubitemid 37407979)
49. Weng NP. Aging of the immune system: how much can the adaptive immune system adapt? Immunity 2006; 24 (5): 495-499
50. Bryl E, Vallejo AN, Weyand CM, et al. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001; 167 (6): 3231-3238
51. Fasth AER, Cao D, van Vollenhoven R, et al. CD28 (null) CD4 (+) T cells: characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Rheumatol 2004; 60 (1-2): 199-208
52. Yung RL. Changes in immune function with age. Rheum Dis Clin North Am 2000; 26 (3): 455-469
53. Daynes RA, Araneo BA, Ershler WB, et al. Altered regulation of Il-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sulphated derivative. J Immunol 1993; 150 (12): 5219-5230
54. Foster KD, Conn CA, Kluger MJ. Fever, tumor-necrosisfactor, and interleukin-6 in young, mature, and aged Fischer 344 rats. Am J Physiol 1992; 262 (2): R211-5
55. Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998; 102 (2-3): 199-209
56. Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2008; 8 (1): 18-30
57. Donato AJ, Black AD, Jablonski KL, et al. Aging is associated with greater nuclear NFkappaB, reduced I-kappa- B-alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 2008; 7: 805-812
58. Mysliwska J, Bryl E, Foerster J, et al. The upregulation of TNF alpha production is not a generalised phenomenon in the elderly between their sixth and seventh decades of life. Mech Ageing Dev 1999; 107 (1): 1-14 (Pubitemid 29113069)
59. Cutolo M, Montecucco CM, Cavagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006 Nov; 65 (11): 1438-1443 (Pubitemid 44629119)
60. Horiuchi T, Yoshida T, Koshihara Y, et al. The increase of parathyroid hormone-related peptide and cytokine levels in synovial fluid of elderly rheumatoid arthritis and osteoarthritis. Endocr J 1999; 46 (5): 643-649
61. Punzi L, Bertazzolo N, Pianon M, et al. Synovial fluid levels of proinflammatory interleukins and their interrelationships in elderly vs younger onset rheumatoid arthritis. Aging Clin Exp Res 1996; 8 (4): 277-281 (Pubitemid 126790748)
62. Chen DY, Hsieh TY, Chen YM, et al. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 2008; 55 (3): 250-258
63. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel®) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003; 30 (4): 691-696
64. Bathon JM, Fleischmann RM, van der Heijde DM, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33 (2): 234-243 (Pubitemid 43209297)
65. Schiff MH, Yu EB, Weinblatt ME, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23 (2): 167-178
66. Genevay S, Finckh A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a populationbased cohort study. Arthritis Rheum 2007; 57 (4): 679-685 (Pubitemid 46764060)
67. Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of anti-TNFa therapy in rheumatoid arthritis. Ann Rheum Dis. Epub 2008 Nov 19
68. Filippini M, Bazzani C, Zingarelli S, et al. Anti-TNFalpha agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients [in Italian]. Reumatismo 2008; 60 (1): 41-49
69. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337 (3): 141-147 (Pubitemid 27306284)
70. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130 (6): 478-486 (Pubitemid 29135800)
71. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (5 Suppl. 39): S93-9 (Pubitemid 46657516)
72. Fransen J, Langenegger T, Michel BA, et al. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 2000; 39 (3): 321-327 (Pubitemid 30204219)
73. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65 (3): 379-384 (Pubitemid 43268229)
74. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology 2005; 44 (5): 695-696 (Pubitemid 41487252)
75. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Antitumor necrosis factor alpha therapy and the risk of severe bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 6: 1754-1764
76. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older onset rheumatoid arthritis receive less aggressive treatment than younger patients? Ann Rheum Dis 2006; 65 (9): 1226-1229
77. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46 (7): 1157-1160 (Pubitemid 47050621)
78. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology 2006; 45 (12): 1555-1557
79. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46 (9): 2294-2300
80. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNF treatment in RA patients: clinical practice experience. Autoimmun Rev 2009; 8 (3): 266-273
81. Guralnik JM. Assessing the impact of comorbidity in the older population. Ann Epidemiol 1996; 6 (5): 376-380
82. Jacobsson LTH, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (7): 1213-1218 (Pubitemid 40995372)
83. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56 (9): 2905-2912 (Pubitemid 47502736)
84. Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective openlabel pilot study. Rheumatology (Oxford) 2005; 44 (12): 1546-1548 (Pubitemid 41742473)
85. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 420-427 (Pubitemid 43989885)
86. Fraenkel L, Bogardus ST, Concato J, et al. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004; 63 (11): 1372-1378 (Pubitemid 39433938)
87. Fraenkel L, Bogardus S, Concato J, et al. Risk communication in rheumatoid arthritis. J Rheumatol 2003; 30 (3): 443-448
88. Ho M, Lavery B, Pullar T. The risk of treatment: a study of rheumatoid arthritis patients' attitudes. Br J Rheumatol 1998; 37 (4): 459-460 (Pubitemid 28372205)